Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Cancers · 20.01.2024 · 16 (2) · 447
DOI: 10.3390/cancers16020447 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 20.01.2024. Verfasst von Virginia Metrangolo und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Finsen Laboratory, Rigshospitalet, DK-2200 Copenhagen, Denmark. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Danish Cancer Society, the Simon Fougner Hartmanns family foundation.
Abstract (Originalsprache)
Introduced almost two decades ago, ADCs have marked a breakthrough in the targeted therapy era, providing clinical benefits to many cancer patients. While the inherent complexity of this class of drugs has challenged their development and broad application, the experience gained from years of trials and errors and recent advances in construct design and delivery have led to an increased number of ADCs approved or in late clinical development in only five years. Target and payload diversification, along with novel conjugation and linker technologies, are at the forefront of next-generation ADC development, renewing hopes to broaden the scope of these targeted drugs to difficult-to-treat cancers and beyond. This review highlights recent trends in the ADC field, focusing on construct design and mechanism of action and their implications on ADCs’ therapeutic profile. The evolution from conventional to innovative ADC formats will be illustrated, along with some of the current hurdles, including toxicity and drug resistance. Future directions to improve the design of next-generation ADCs will also be presented.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Finsen Laboratory, Rigshospitalet, DK-2200 Copenhagen, Denmark.
- Biotech Research & Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
ORCID-Profile: Virginia Metrangolo, Lars H Engelholm
Förderung
- European Union
- Danish Cancer Society
- the Simon Fougner Hartmanns family foundation
- Innovation Foundation
- European Union’s Horizon 2020 research and innovation programme
- Simon Fougner Hartmanns family foundation
- BioInnovation Institute (BII)
Zitieren
APA
Metrangolo, V., & Engelholm, L. H. (2024). Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs. Cancers, 16(2), 447. https://doi.org/10.3390/cancers16020447
Vancouver
Metrangolo V, Engelholm LH. Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs. Cancers. 2024;16(2):447. doi:10.3390/cancers16020447
BibTeX
@article{Metrangolo2024,
author = {Metrangolo, Virginia and Engelholm, Lars H},
title = {Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs},
journal = {Cancers},
year = {2024},
volume = {16},
number = {2},
pages = {447},
doi = {10.3390/cancers16020447}
}
EUVIMED